Abstract
Mexico has experienced one of the highest COVID-19 death rates in the world. A delayed response towards implementation of social distancing interventions until late March 2020 and a phased reopening of the country in June 2020 has facilitated sustained disease transmission in the region. Here, we systematically generate and compare 30-day ahead forecasts using previously validated growth models based on mortality trends from the Institute for Health Metrics and Evaluation for Mexico and Mexico City in near real-time. Moreover, we estimate reproduction numbers for SARS-CoV-2 based on methods that rely on genomic data as well as case incidence data. Subsequently, functional data analysis techniques are utilized to analyze the shapes of COVID-19 growth rate curves at the state level to characterize the spatial-temporal transmission patterns. The early estimates of reproduction number for Mexico were estimated between R∼1.1-from genomic and case incidence data. Moreover, the mean estimate of R has fluctuated ∼1.0 from late July till end of September 2020. The spatial analysis characterizes the state-level dynamics of COVID-19 into four groups with distinct epidemic trajectories. We found that the sequential mortality forecasts from the GLM and Richards model predict downward trends in the number of deaths for all thirteen forecasts periods for Mexico and Mexico City. The sub-epidemic and IHME models predict more realistic stable trajectory of COVID-19 mortality trends for the last three forecast periods (09/21-10/21 - 09/28-10/27) for Mexico and Mexico City. Our findings support the view that phenomenological models are useful tools for short-term epidemic forecasting albeit forecasts need to be interpreted with caution given the dynamic implementation and lifting of social distancing measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
G.C. is partially supported from NSF grants 1610429 and 1633381 and R01 GM 130900
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data for this study is publicly available
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data for short term forecasts is available from the IHME downloadable estimates Data for mobility trends is available from the Apple mobility trends Genomic data is available from the GSAID repository Case incidence data is available from the Ministry of Health, Mexico